Literature DB >> 12120260

Genome-based pharmacogenetics and the pharmaceutical industry.

Allen D Roses1.   

Abstract

Pharmacogenetic capabilities have changed markedly since The SNP Consortium made a dense single-nucleotide polymorphism (SNP) map freely available in 2001. For more than 40 years, pharmacokinetics and pharmacodynamics of drug-metabolizing molecules were the focus of practical applications. Today, it is possible to use SNP-mapping technologies to create a genetic profile of each individual that can be used to identify patterns of susceptibility genes for common diseases as well as genetic risk/efficacy factors that are related to the effects of drugs.

Mesh：

Substances：

Year:  2002        PMID： 12120260     DOI： 10.1038/nrd840

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  16 in total

1.  Two methods of whole-genome amplification enable accurate genotyping across a 2320-SNP linkage panel.

Authors:  David L Barker; Mark S T Hansen; A Fawad Faruqi; Diane Giannola; Orlando R Irsula; Roger S Lasken; Martin Latterich; Vladimir Makarov; Arnold Oliphant; Jonathon H Pinter; Richard Shen; Irina Sleptsova; William Ziehler; Eric Lai
Journal:  Genome Res       Date:  2004-05       Impact factor: 9.043

Review 2.  Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects.

Authors:  Søren M Bentzen; Matthew Parliament; Joseph O Deasy; Adam Dicker; Walter J Curran; Jacqueline P Williams; Barry S Rosenstein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

3.  Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report.

Authors:  O P Corrigan
Journal:  J Med Ethics       Date:  2005-03       Impact factor: 2.903

4.  The future of antidepressant pharmacotherapy.

Authors:  David Baldwin; Chris Thompson
Journal:  World Psychiatry       Date:  2003-02       Impact factor: 49.548

Review 5.  Pharmacogenetics in drug development.

Authors:  Alun D McCarthy; James L Kennedy; Lefkos T Middleton
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

Review 6.  Implications of genetic research on the role of the serotonin in depression: emphasis on the serotonin type 1A receptor and the serotonin transporter.

Authors:  Alexander Neumeister; Theresa Young; Juergen Stastny
Journal:  Psychopharmacology (Berl)       Date:  2004-07-13       Impact factor: 4.530

7.  Genome-scale analysis reveals Sst2 as the principal regulator of mating pheromone signaling in the yeast Saccharomyces cerevisiae.

Authors:  Scott A Chasse; Paul Flanary; Stephen C Parnell; Nan Hao; Jiyoung Y Cha; David P Siderovski; Henrik G Dohlman
Journal:  Eukaryot Cell       Date:  2006-02

8.  Generating genome-scale candidate gene lists for pharmacogenomics.

Authors:  N T Hansen; S Brunak; R B Altman
Journal:  Clin Pharmacol Ther       Date:  2009-04-15       Impact factor: 6.875

Review 9.  Gene polymorphisms within the immune system that may underlie drug allergy.

Authors:  Rob J Vandebriel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-03       Impact factor: 3.000

10.  Whole genome amplification of DNA from laser capture-microdissected tissue for high-throughput single nucleotide polymorphism and short tandem repeat genotyping.

Authors:  Martha S Rook; Scott M Delach; Galina Deyneko; Andrew Worlock; Jia Liu Wolfe
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.